Is there a generic for Atripla?

When will a generic for Atripla become available?

Atripla, a combination medication comprising efavirenz, emtricitabine, and tenofovir disoproxil fumarate, is used to treat HIV-1 infection [1]. The patent for Atripla, which is owned by Gilead Sciences, is set to expire in 2020 in the United States, but has variously expired in different parts of the world.

How long do generic versions usually take to enter the market after patent expiry?

Once a patent expires, generic manufacturers can begin producing and marketing their own versions of the medication. Generally, generic versions enter the market within 1-3 years after patent expiry [2].

Has Gilead challenged the expiration of Atripla's patent?

Gilead has faced legal challenges to its patents for various HIV medications, including Atripla [3]. However, it appears that Gilead's attempts to extend patent protection for Atripla have been unsuccessful.

What does this mean for access to Atripla?

The availability of generic Atripla will likely reduce the cost of treatment for patients, making HIV medication moreaccessible in low- and middle-income countries. Generic manufacturers such as Teva, Mylan, and Cipla have already filed applications with regulatory agencies to produce generic versions of Atripla.

Sources:

[1] https://www.drugpatentwatch.com/DrugPatentWatch/drug/atripla

[2] https://www.generics.com/generics-basics/how-long-does-it-take-for-a-generic-to-enter-the-market/

[3] https://www.reuters.com/article/us-gilead-sciences-patent-idUSKBN1H21B3